132 related articles for article (PubMed ID: 28454423)
1. The nutritional herb
Telang NT; Li G; Katdare M; Sepkovic DW; Bradlow HL; Wong GYC
Oncol Lett; 2017 Apr; 13(4):2477-2482. PubMed ID: 28454423
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of Chinese nutritional herbs in isogenic breast carcinoma cells with modulated estrogen receptor function.
Telang N; Li G; Katdare M; Sepkovic D; Bradlow L; Wong G
Oncol Lett; 2016 Nov; 12(5):3949-3957. PubMed ID: 27895755
[TBL] [Abstract][Full Text] [Related]
3. Anti-proliferative effects of Chinese herb Cornus officinalis in a cell culture model for estrogen receptor-positive clinical breast cancer.
Telang NT; Li G; Sepkovic DW; Bradlow HL; Wong GY
Mol Med Rep; 2012 Jan; 5(1):22-8. PubMed ID: 21971582
[TBL] [Abstract][Full Text] [Related]
4. The Divergent Effects of Ovarian Steroid Hormones in the MCF-7 Model for Luminal A Breast Cancer: Mechanistic Leads for Therapy.
Telang NT
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563193
[TBL] [Abstract][Full Text] [Related]
5. Growth inhibitory efficacy and anti-aromatase activity of
Telang N; Nair HB; Wong GYC
Biomed Rep; 2019 Nov; 11(5):222-229. PubMed ID: 31632670
[TBL] [Abstract][Full Text] [Related]
6. Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism.
Li G; Sepkovic DW; Bradlow HL; Telang NT; Wong GY
Nutr Cancer; 2009; 61(3):408-14. PubMed ID: 19373615
[TBL] [Abstract][Full Text] [Related]
7. Anti-estrogenic effect of unliganded progesterone receptor is estrogen-selective in breast cancer cells MCF-7.
Zheng ZY; Lin VC
Cancer Lett; 2008 Sep; 268(2):202-11. PubMed ID: 18477500
[TBL] [Abstract][Full Text] [Related]
8. Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer.
Telang N
Oncol Lett; 2018 Oct; 16(4):5489-5497. PubMed ID: 30214619
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines.
Cho HS; NG PA; Katzenellenbogen BS
Mol Endocrinol; 1991 Sep; 5(9):1323-30. PubMed ID: 1722871
[TBL] [Abstract][Full Text] [Related]
10. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
Bhat KP; Lantvit D; Christov K; Mehta RG; Moon RC; Pezzuto JM
Cancer Res; 2001 Oct; 61(20):7456-63. PubMed ID: 11606380
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of extracts from Lycium barbarum bark and fruit on estrogen receptor positive human mammary carcinoma MCF-7 cells.
Telang N; Li G; Sepkovic D; Bradlow HL; Wong GY
Nutr Cancer; 2014; 66(2):278-84. PubMed ID: 24377707
[TBL] [Abstract][Full Text] [Related]
12. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
13. In Vitro and In Vivo Modulation of Growth Regulation in the Human Breast Cancer Cell Line MCF-7 by Estradiol Metabolites.
Suto A; Telang NT; Tanino H; Takeshita T; Ohmiya H; Osborne MP; Kubota T
Breast Cancer; 1999 Apr; 6(2):87-92. PubMed ID: 11091698
[TBL] [Abstract][Full Text] [Related]
14. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
15. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
16. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine kinase inhibitors as antiproliferative agents against an estrogen-dependent breast cancer cell line in vitro.
Twaddle GM; Turbov J; Liu N; Murthy S
J Surg Oncol; 1999 Feb; 70(2):83-90. PubMed ID: 10084649
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast Cancer.
Van Asten K; Slembrouck L; Olbrecht S; Jongen L; Brouckaert O; Wildiers H; Floris G; Van Limbergen E; Weltens C; Smeets A; Paridaens R; Giobbie-Hurder A; Regan MM; Viale G; Thürlimann B; Vergote I; Christodoulou E; Van Calster B; Neven P
Oncologist; 2019 Feb; 24(2):165-171. PubMed ID: 30171067
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid synthase in breast and endometrial cancer: An alternative to selective estrogen receptor modulators?
Lupu R; Menendez JA
Endocrinology; 2006 Sep; 147(9):4056-66. PubMed ID: 16809439
[TBL] [Abstract][Full Text] [Related]
20. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
